Multiple Myeloma

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bone.

What is Multiple Myeloma?

Multiple myeloma is a form of cancer that affects the bone marrow. The cancer is also called Kahler’s disease, named after an Austrian pathologist called Otto Kahler who first described the condition.

Multiple Myeloma Diagnosis

Multiple Myeloma Pathophysiology

Multiple Myeloma Treatment

Multiple Myeloma Epidemiology

Multiple Myeloma Symptoms

Management of Myeloma

Multiple Myeloma Imaging Strategies

Latest Multiple Myeloma News and Research

Metabolic vulnerabilities in malignant cells may lead to new breast cancer therapies

Metabolic differences could explain why some metastatic breast cancer cells rapidly generate tumors after migrating from primary tumors to the brain, while others linger for months or years before forming these secondary tumors, UT Southwestern scientists report in a new study.

12 Jan 2022

Efficacy of COVID-19 convalescent plasma therapy in patients with hematological malignancies and COVID-19

Scientists recently demonstrated the efficacy of COVID-19 convalescent plasma therapy in improving the survival rate among patients with B-cell lymphoid malignancy and COVID-19.

5 Jan 2022

$Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma$

Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma

Early results from an Alliance for Clinical Trials in Oncology randomized clinical trial of adults with multiple myeloma relapsing on frontline lenalidomide therapy showed that adding ixazomib (Ninlaro®) to pomalidomide and dexamethasone as part of second line therapy extended the length of time patients lived before their disease worsened (progression-free survival) compared with patients who received pomalidomide and dexamethasone.

21 Dec 2021

COVID-19 vaccines offer protection for multiple myeloma patients, but lesser than other cancer survivors

For patients with the blood cancer multiple myeloma, vaccination against COVID-19 provides some protection against coronavirus infection but to a far lower degree than the general population of cancer survivors, a new study by Dana-Farber Cancer Institute investigators shows.

13 Dec 2021

Large study reveals increased rates of myeloma precursor condition in high-risk groups

The first results from the largest screening study yet conducted in the United States of individuals at above-average risk for the blood cancer multiple myeloma have revealed higher rates of a myeloma precursor condition in older adults who are Black or who have a close family member with a current or past blood cancer.

13 Dec 2021

Potentially serious side effect reported after CAR-T cell therapy for multiple myeloma

Mount Sinai scientists have become the first to report a potentially serious side effect related to a new form of immunotherapy known as CAR-T cell therapy, which was recently approved for the treatment of multiple myeloma.

11 Dec 2021

NYU Langone opens new state-of-the-art center to treat patients with blood cancers

NYU Langone Health's Laura and Isaac Perlmutter Cancer Center opened a new state-of-the-art center to treat people with blood cancers, including leukemia, lymphoma, and multiple myeloma.

29 Nov 2021

Combination of two targeted drugs shows "clinically meaningful" activity in some malignant brain tumors

A combination of two targeted cancer drugs showed unprecedented, "clinically meaningful" activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.

25 Nov 2021

Study shows vaccinated multiple myeloma patients at greater risk of breakthrough SARS-CoV-2 infections

Researchers recently published a study assessing the risks of patients with MM to breakthrough infections after completing their vaccination schedule compared to those without any form of cancer.

25 Nov 2021

Exosomes involved in the progression of breast cancer in patients with obesity, diabetes

Obesity, insulin resistance and Type 2 diabetes are risk factors for breast cancer in post-menopausal women. The metabolic and inflammatory complications of obesity have a role in the formation of cancer.

24 Nov 2021

Red blood cell distribution width as a biomarker for COVID-19

A review highlights the prospects and challenges of RDW as a predictive biomarker for viral infections, with a special focus on COVID-19 and hepatitis.

22 Nov 2021

Researchers identify never-before-defined subtypes of a blood cancer

Mount Sinai researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for never-before-defined subtypes of a blood cancer called multiple myeloma.

17 Nov 2021

Washington University School of Medicine receives $17 million to address disparities in cancers

Washington University School of Medicine in St. Louis has received a $17 million grant from the National Institutes of Health to address disparities in cancer research, treatment and outcomes in underrepresented populations.

6 Nov 2021

Despite restraints, democrats’ drug pricing plan could still aid consumers

The Medicare prescription drug pricing plan Democrats unveiled this week is not nearly as ambitious as many lawmakers sought, but they and drug policy experts say the provisions crack open the door to reforms that could have dramatic effects.

5 Nov 2021

What do we really know about vaccine effectiveness?

The politicization of covid vaccines — and, well, just about everything else having to do with the pandemic — has led to confusion, if not utter fatigue.

2 Nov 2021

COVID-19 vaccine-elicited immune responses in myeloma patients

Researchers collaborated to address these evidence gaps by initiating a web-based prospective study of adults diagnosed with multiple myeloma to determine the immune response to the first and second dose of the COVID-19 vaccine.

27 Oct 2021

Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals

Israeli researchers evaluate the antibody response in ICPs to assess antibody-mediated immunity following vaccination with the Pfizer-BioNTech vaccine.

26 Oct 2021

WHO's new List of Essential Medicines prioritizes access to diabetes and cancer treatments

WHO today published the new edition of its Model Lists of Essential Medicines and Essential Medicines for Children, which include new treatments for various cancers, insulin analogues and new oral medicines for diabetes, new medicines to assist people who want to stop smoking, and new antimicrobials to treat serious bacterial and fungal infections.

1 Oct 2021

Research provides the basis for an additional novel immunotherapy for multiple myeloma patients

Oncotarget published "Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma" which reported that Multiple Myeloma patients suffer disease relapse due to the development of therapeutic resistance. Increasing evidence suggests that immunotherapeutic strategies can provide durable responses.

29 Sep 2021

Those undergoing treatment for hematological malignancies show reduced immune response to COVID-19 vaccines

Researchers recently investigated the effect of infection with SARS-CoV-2 in patients with hematologic malignancies in minority populations.

21 Sep 2021

Multiple Myeloma

Overview

Multiple Myeloma Diagnosis

Multiple Myeloma Pathophysiology

Multiple Myeloma Treatment

Feature Articles

Multiple Myeloma Epidemiology

Multiple Myeloma Symptoms

Management of Myeloma

Multiple Myeloma Imaging Strategies

Latest Multiple Myeloma News and Research

Metabolic vulnerabilities in malignant cells may lead to new breast cancer therapies

Efficacy of COVID-19 convalescent plasma therapy in patients with hematological malignancies and COVID-19

Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma

COVID-19 vaccines offer protection for multiple myeloma patients, but lesser than other cancer survivors

Large study reveals increased rates of myeloma precursor condition in high-risk groups

Potentially serious side effect reported after CAR-T cell therapy for multiple myeloma

NYU Langone opens new state-of-the-art center to treat patients with blood cancers

Combination of two targeted drugs shows "clinically meaningful" activity in some malignant brain tumors

Study shows vaccinated multiple myeloma patients at greater risk of breakthrough SARS-CoV-2 infections

Exosomes involved in the progression of breast cancer in patients with obesity, diabetes

Red blood cell distribution width as a biomarker for COVID-19

Researchers identify never-before-defined subtypes of a blood cancer

Washington University School of Medicine receives $17 million to address disparities in cancers

Despite restraints, democrats’ drug pricing plan could still aid consumers

What do we really know about vaccine effectiveness?

COVID-19 vaccine-elicited immune responses in myeloma patients

Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals

WHO's new List of Essential Medicines prioritizes access to diabetes and cancer treatments

Research provides the basis for an additional novel immunotherapy for multiple myeloma patients

Those undergoing treatment for hematological malignancies show reduced immune response to COVID-19 vaccines

How has COVID-19 Impacted our Economy?

Using lab-grown stomachs to shed light on the symptoms of COVID-19

Developing a 'Fingerprint' test that could diagnose Alzheimer’s early

Multiple Myeloma

Overview

Feature Articles

Multiple Myeloma Epidemiology

Multiple Myeloma Symptoms

Management of Myeloma

Multiple Myeloma Imaging Strategies

Latest Multiple Myeloma News and Research

Newsletters you may be interested in